Overview

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Status:
Terminated

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.

Phase:

Phase 1

Details

Lead Sponsor:

Exelixis